newsfilter
← Latest News
GlobeNewswire·

IsoPlexis Partners with MediMergent and The Center for Cancer and Blood Disorders in Study of AZD7442 for Prevention of COVID-19 Infection in Immuno-Compromised Cancer Patients

BRANFORD, Conn., Sept. 06, 2022 (GLOBE NEWSWIRE) -- IsoPlexis (NASDAQ: ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today announced a partnership with MediMergent, LLC, and The Center for Can